Maria Moscvin

@UChicagoHemOnc Fellow | alum @StanfordMedRes @TheBianchiLab @unito 🇮🇹

[UChicagoCancerCenter @UCCancerCenter]

Today at #ASCO26, Betul Gok Yavuz, MD, PhD is presenting during the poster session. Stop by to learn more about how somatic copy-number alterations may help identify biomarkers for risk stratification and clinical decision-making in #RCC brain metastases. @UChicagoUrology

[UChicagoCancerCenter @UCCancerCenter]

Congratulations to our #ASCO26 Young Investigator Award recipients:
Margarite Matossian, MD, PhD (@MargariteMatos1)
Reid Shaw, MD
Sulin Wu, MD, PhD (@SulinWu_oncgene)
Maeve Hennessey, MBBCh, BAO (@HennessyMaeve)
Hannah Johnston, MD (@HJohnstonMD)

[University of Chicago Hem/Onc Fellows @UCHemOncFellows]

#FellowshipRetreat is a time to relax, reconnect, and network as we learn about job search, transitioning into faculty, collaboration, mentorship, and the future of our field.
Thank you to our invited panelists and @UChicagoHemOnc Alumni.

[UChicagoCancerCenter @UCCancerCenter]

Congratulations to our rising stars, Loren Saulsberry, PhD, and Ben Derman, MD, on receiving the 40 Under 40 in Cancer award. 🎉
@bdermanmd @lsaulsbe @UChicagoPHS
@UChicagoHemOnc @UChicagoMed

[Maria Moscvin @MMoscvin]

@AuclairDan Adding James Hoffman

[UChicagoCancerCenter @UCCancerCenter]

We are one year away from opening the AbbVie Foundation Cancer Pavilion!

[Masooma Rana @MasoomaRana_]

Funded two-year research position is available, focusing on cancer cell therapy in lymphoma and multiple myeloma. This position is open to candidates who do not require visa sponsorship. Please feel free to DM with any questions! @Inside_TheMatch

[Vincent Rajkumar @VincentRK]

Many leaders in medicine are focused on AI and how it’s going to solve problems in medicine. Maybe.

But doctors with great clinical acumen, empathy, and the wisdom to make the right judgment call are the ones we need more of, and who patients want and seek out. This is the important stuff.

[Jiaqi Li, MD @jiaqi_liMD]

Excited to present another poster at #ACC26 on prior myocardial injury and clinical outcomes in ICI-associated myocarditis! Grateful for the support of my amazing mentor @HanZhuMD, thank you to @Ron_Witteles for stopping by, and always proud to represent @StanfordMedRes

[Orly Leiva, MD @LeivaOrly]

I 💯 agree. Cancer diagnosis by itself should not be a strict contra indication to ECMO or other MCS. Cardio-oncology/oncology input in these patients is vital!

[Maria Moscvin @MMoscvin]

Proof that we are surviving 1st year fellowship, not only surviving but kind of thriving @UChicagoHemOnc

[UChicagoCancerCenter @UCCancerCenter]

Kudos to @UCCancerCenter current trainees, Samuel Yates, MD, MS, Habib El-Khoury, MD and former trainee, Andrew Palmer, MD on receiving #ASH25 Abstract Achievement Award.👏👏👏
#fight4hematology @UChicagoLeuk @UCHemOncFellows @UChicagoHemOnc

[Maria Moscvin @MMoscvin]

@UCHemOncFellows first year fellows learning hematology things from the one and only breast oncologist Dr. Olopade at #ASH25

[UChicagoCancerCenter @UCCancerCenter]

At #ASH25, Ben Derman, MD, ⁦(@bdermanmd⁩) emphasizes that pts with sustained deep MRD negativity and no high-risk features may safely discontinue maintenance therapy, as MRD-guided monitoring helps personalize treatment in multiple myeloma. ⁦⁩ ⁦@UChicagoHemOnc⁩

[Maria Moscvin @MMoscvin]

@StanfordMedRes alumni reunite at #ASH2025 🩸@Ron_Witteles @StanfordChiefs @StanfordMed

[University of Chicago Hem/Onc Fellows @UCHemOncFellows]

'Super excited to welcome and congratulate our incoming fellowship class. We can't wait to have you join the program next summer! #fellowshipmatch2025 @TheNRMP

[Maria Moscvin @MMoscvin]

@nursariipek @UCHemOncFellows A true Turkish girl spots the goodies from miles away

[Maria Moscvin @MMoscvin]

Celebrating Friendsgiving with the best first year @UCHemOncFellows crew. Grateful for this journey and these people! We missed Bukky and Shree🥹

[Maria Moscvin @MMoscvin]

@nursariipek @ASH_hematology @vangalenlab @BrighamWomens @YaleIM_Chiefs Yess, annual breakfast before talks as tradition

[Vincent Rajkumar @VincentRK]

HISTORIC AND PARADIGM CHANGING:

FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication.

Excellent news and thanks to @JNJInnovMed and the huge worldwide team of investigators for making it happen. @thanosdimop @SagarLonialMD @PlasmaCellPete